Rochester,NY 7/11/2009 2:27:20 AM
Afternoon Stock Report - BIIB - Get Ready for a 25% Drop - Sourced WhisperFromWallStreet.com
Biogen Idec Inc.
Afternoon Stock Report - BIIB - Get Ready for a 25% Drop - Sourced WhisperFromWallStreet.com
Biogen Idec Inc. BIIB
Back in July of 1995, this friend -- let's call him Charlie -- bought Microsoft at what turned out to be the highest price it would reach that year. The stock was down 15% in no time, and Charlie was worried. He was smart enough to know the market is the best wealth-creating machine available to us regular folks, but he felt about stocks the way Elizabeth Taylor felt about husbands. He liked them well enough, but he tended to give up when things got a little rocky.
In a matter of weeks his paper loss was approaching 25%, and he couldn't stand it anymore. He bailed out.
Needless to say, the next few years were even rougher on Charlie as he watched Mr. Softy march steadily higher. It achieved 10-bagger status at the height of the bull market in 2000, but even today it has returned more than 220% from when he sold.
Last Trade: 44.92
Day's Range: 44.53 - 45.80
52wk Range: 37.21 - 73.59
Volume: 1,986,997
ABOUT - Gran Tierra Energy
Biogen Idec Inc., a biotechnology company, develops, manufactures, and commercializes novel therapeutics in the areas of oncology, neurology, immunology, and cardiology in the United States and internationally. The company's marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, low-grade or follicular, CD20-positive, and B-cell Non-Hodgkin's Lymphoma (NHL); TYSABRI to treat relapsing MS; and FUMADERM for the treatment of severe psoriasis. Its products under development consist of BG-12, a Phase III clinical trial product for the treatment of MS; Anti-CD80 MAb, a Phase III clinical trial product for the treatment of relapsed NHL; Anti-CD23 MAb, a Phase II/III clinical trial product for the treatment of relapsed or refractory chronic lymphocytic leukemia; Humanized Anti-CD20 MAb, a Phase III clinical trial product for the treatment of rheumatoid arthritis and lupus nephritis; Lixivaptan, a Phase III clinical drug for the treatment of Acute Hyponatremia; and ADENTRI, a Phase III clinical trial product for acute decompensated heart failure patients with renal insufficiency.
---
During 2009 we have sent 40+ alerts with an average gain of over 80%. Below are a few alerts sent only to our whisperfromwallstreet.com members.
SPNG 1800%
AMNG 241%
RKBD 300%
UTRM 169%
TLLE 266%
Sign up now to receive free stock alerts
---
Please Read Our Disclaimer at http://whisperfromwallstreet.com/disclaimer.php
